Catalyst Pharmaceuticals, Inc. (CPRX) — Financial statements
Income statement, balance sheet, and cash flow for Catalyst Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 589↑19.8% | 492↑23.5% | 398↑85.9% | 214↑52.1% | 141 | |
| Cost of Revenue | 87↑26.7% | 69↑32.5% | 52↑51.1% | 34↑57.2% | 22 | |
| Gross Profit | 502↑18.6% | 423↑22.1% | 346↑92.6% | 180↑51.2% | 119 | |
| Operating Expenses | ||||||
| R&D Expenses | 13↑0.5% | 13↓86.4% | 93↑370.7% | 20↑16.8% | 17 | |
| General & Administrative Expenses | 72↓57.4% | 168↑256.7% | 47↓12.6% | 54↑129.1% | 23 | |
| Selling & Marketing Expenses | 122↑1122.4% | 10↓88.5% | 87↑2526.9% | 3↓87.4% | 26 | |
| SG&A Expenses | 194↑9.0% | 178↑32.9% | 134↑134.2% | 57↑15.0% | 50 | |
| Other Expenses | 37↑0.3% | 37↑14.8% | 33↑2865.8% | 1 | 0.00 | |
| Operating Expenses | 244↑7.1% | 228↓12.2% | 259↑232.7% | 78↑17.1% | 67 | |
| Total Costs & Expenses | 331↑11.7% | 297↓4.7% | 311↑177.1% | 112↑27.0% | 88 | |
| Operating Results | ||||||
| Operating Income | 258↑32.1% | 195↑124.8% | 87↓14.8% | 102↑94.4% | 52 | |
| Depreciation & Amortization | 38↑0.3% | 38↑14.9% | 33↑2553.8% | 1↑545.3% | 0.19 | |
| EBITDA | 296↑26.9% | 233↑94.6% | 120↑16.1% | 103↑96.0% | 53 | |
| EBIT | 258↑32.1% | 195↑124.8% | 87↓14.8% | 102↑94.4% | 52 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00↓100.0% | 16 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 0.00↓100.0% | 16 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 26↑21.8% | 21↑174.6% | 8↑167.2% | 3↑921.6% | 0.28 | |
| Income Before Tax | 284↑31.1% | 216↑128.8% | 95↓9.7% | 105↑98.8% | 53 | |
| Income Tax Expense | 69↑32.1% | 52↑126.7% | 23↑6.8% | 22↑64.1% | 13 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 214↑30.8% | 164↑129.5% | 71↓14.0% | 83↑110.4% | 39 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 214↑30.8% | 164↑129.5% | 71↓14.0% | 83↑110.4% | 39 | |
| Bottom-Line Net Income | 214↑30.8% | 164↑129.5% | 71↓14.0% | 83↑110.4% | 39 | |
| EPS (Basic) | 1.75↑26.8% | 1.38↑106.0% | 0.67↓16.3% | 0.80↑110.5% | 0.38 | |
| EPS (Diluted) | 1.68↑28.2% | 1.31↑107.9% | 0.63↓16.0% | 0.75↑102.7% | 0.37 | |
| Weighted Average Shares | 122↑3.2% | 118↑11.5% | 106↑2.8% | 103↓0.0% | 103 | |
| Weighted Average Diluted Shares | 127↑1.9% | 125↑9.8% | 114↑2.1% | 111↑3.3% | 108 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.